|Mr. Haruo Naito||Chief Exec. Officer, Representative Corp. Officer and Director||1.17M||N/A||70|
|Gary Hendler||Chief Commercial Officer-Oncology Bus., SVP, Pres-EMEA & Eisai Global Oncology Bus.||987.23k||N/A||51|
|Dr. Lynn D. Kramer M.D., FAAN||Chief Clinical Officer & Chief Medical Officer of Neurology Bus. Group and VP||1.06M||N/A||67|
|Mr. Alexander Scott||VP and Chief Strategy Officer & Head of Strategy Dept - Neurology Bus. Group||640.37k||N/A||N/A|
|Ms. Shaji Procida||VP, Pres of Eisai Inc and Chief Operating Officer of Eisai Inc||853.82k||N/A||46|
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. The company offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimers disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment. It also provides Lunesta, a non-benzodiazepine hypnotic agent for insomnia treatment; Pariet, a proton pump inhibitor; HUMIRA, a human anti-TNF-a monoclonal antibody; and epilepsy franchise products, including Zonegran, Zebinix, Fycompa, and Inovelo, which are antiepileptic agents. In addition, the company offers Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome; Actonel, an osteoporosis treatment; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. It has strategic partnerships with Quintiles Inc. for developing six types of anticancer compound candidates; and Epizyme, Inc. to discover, develop, and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically defined patients. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Eisai Co., Ltd.’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 10; Compensation: 4.